Sequentify

Company Overview

Snapshot

Founded in January 2021 by Tom Fleischer, Tamir Biezuner, and Ophir Herbst, Sequentify operates with 1-10 employees. The company has raised $11.1 million across three funding rounds. In January 2024, Sequentify secured a grant from the Israel Innovation Authority to develop a targeted sequencing panel for infectious disease research.

Business overview

Sequentify specializes in developing genomic sample processing products and technologies that precede sequencing hardware loading. The company's core offering, including its InfiniSeq platform, aims to make targeted DNA sequencing as common, fast, and affordable as a blood test. This technology facilitates scalable genomic testing for applications in oncology, screening, and infectious diseases, serving the clinical market within the Health Tech & Life Sciences sector.

Strategic signal

In June 2025, Sequentify partnered with Bio Molecular Systems (BMS) to release the InfiniSeq Protocol for the Myra liquid handling system, combining Sequentify's targeted sequencing chemistry with BMS's automation technology. This collaboration enables high-throughput library preparation, preparing up to 96 indexed libraries in a single run, which significantly reduces hands-on time and errors for clinical and research applications. This signals a strategic move towards broader market accessibility and efficiency in genomic testing, enhancing the company's competitive position by streamlining laboratory workflows.

Company Intelligence Q&A

What was a key strategic partnership for Sequentify in 2025?

In June 2025, Sequentify partnered with Bio Molecular Systems (BMS) to launch the InfiniSeq Protocol for the Myra liquid handling system. This collaboration integrates Sequentify's targeted sequencing chemistry with BMS's automation technology, enabling high-throughput library preparation for clinical and research applications.

What was a significant leadership appointment for Sequentify in 2025?

In July 2025, Sequentify appointed Dr. Ravi Majeti, a renowned expert in hematologic malignancies and a faculty member at Stanford University, as a Scientific Advisor. His expertise is expected to support the expansion of Sequentify's hematology-focused NGS panels and promote the adoption of its genomic testing solutions.

What initiative did Sequentify launch in April 2025 to support genomic studies?

In April 2025, Sequentify announced research grants to accelerate high-impact genomic studies using its scalable targeted library preparation technology. The company invited proposals from research groups focusing on areas like oncology, rare diseases, and infectious diseases, offering reagents for up to 10,000 samples and access to its analysis software.

What was a notable partnership for Sequentify in September 2024?

In September 2024, Sequentify partnered with Sheba Medical Center's Hematology Laboratory and other clinicians to conduct a joint study. This study utilizes Sequentify's InfiniSeq™ Myeloid Malignancies Panel to detect Clonal Hematopoiesis of Indeterminate Potential (CHIP) in cancer patients.

What funding did Sequentify receive in January 2024?

In January 2024, Sequentify was awarded a grant from the Israel Innovation Authority. This funding supports a $1.3 million project focused on developing Sequentify's targeted sequencing panel for infectious disease research, aiming for a rapid, culture-free pathogen detection solution.